First-Line Regimens With Endocrine Therapy Show Benefits in Breast Cancer

TUESDAY, Dec. 20, 2022 -- First-line regimens with endocrine therapy (ET) may be associated with benefits among patients with human epidermal growth factor receptor 2-positive (ERBB2-positive [formerly HER2-positive]) metastatic breast cancer (MBC),...